Progestational 3-(6,6-ethylene-17B-hydroxy-3-oxo-17A-pregna-4-ene-17A-yl)propionic acid G-lactones

Inventors

Nickisch, Klaus • Rao, Pemmaraju • Narkunan, Kesavaram • Cessac, James

Assignees

Evestra Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-8222237-B2

Patent

Publication Date

2012-07-17

Expiration Date


Abstract

Described herein are 3-(6,6-ethylene-17β-hydroxy-3-oxo-17α-pregna-4-ene-17α-yl)propionic acid γ-lactone derivatives having progestational and aldosterone antagonistic activity. Also described herein are methods of preparing and using these novel compounds.

Core Innovation

The disclosure describes synthetic transformations that access steroidal progestogen structures defined by specific double-bond and methylene-bridge patterns. It provides dehydrogenation to give Δ4,9(11)-3-one derivatives, where the dotted line in the relevant structures indicates a double bond between carbons 9 and 11 or between carbons 11 and 12. It also provides methylene-ylid conversions, including sulfur ylids and phosphorus ylids, to convert double-bond precursors to CH2-bridged targets.

The transformations further include fluorination and bromination to obtain an 11-fluoro,9-bromo intermediate followed by debromination to 11β-fluoro derivatives. Additional dehydrogenation and ylid methylenation steps provide other target general formulas. The described synthetic sequences are tied to controlling the structural features corresponding to R1/R2 and R3/R4 options shown in formula-based progestogen structures.

The document also describes oral contraceptive regimen embodiments using the progestogen compounds of the formula definitions, optionally in combination with an estrogen compound. The described regimens include embodiments in which the progestogen is administered in an oral dosage form and cyclic administration over a period that includes 21 consecutive days of active dosing and a defined 7-day interval with either no active agent or an estrogen-containing daily unit.

Claims Coverage

The document includes four independent claims covering specific progestogen compound structures of formula (II), a method of producing a contraceptive state using oral administration of a formula (II) progestogen, specific progestogen compound structures of formula (V), and a method of producing a contraceptive state using oral administration of a formula (V) progestogen. Across these claims, the structural coverage focuses on four variable substituent/bond positions defined as R1/R2 and R3/R4, including hydrogen, an additional bond between specified carbons, or a CH2 bridge between specified carbon pairs.

Progestogen compound defined by formula (ii) structural variables

A progestogen compound having the structure of formula (II) in which the dotted line represents a double bond between carbons 9 and 11 or between carbons 11 and 12, R1 and R2 are hydrogens, an additional bond between carbons 1 and 2, or a CH2 bridge between carbons 1 and 2, and R3 and R4 are hydrogens or a CH2 bridge between carbons 15 and 16.

Oral administration of a formula (ii) progestogen to produce a contraceptive state

A method of producing a contraceptive state in a subject by administering to the subject in need of an oral dosage form comprising an effective amount of a progestogen compound of formula (II) where the dotted line represents a double bond between carbons 9 and 11 or between carbons 11 and 12; R1 and R2 are hydrogens, an additional bond between carbons 1 and 2, or a CH2 bridge between carbons 1 and 2; and R3 and R4 are hydrogens or a CH2 bridge between carbons 15 and 16.

Progestogen compound defined by formula (v) structural variables

A progestogen compound of formula (V) wherein R1 and R2 are hydrogens, an additional bond between carbons 1 and 2, or a CH2 bridge between carbons 1 and 2; and R3 and R4 are hydrogens or a CH2 bridge between carbons 15 and 16.

Oral administration of a formula (v) progestogen to produce a contraceptive state

A method of producing a contraceptive state in a subject by administering to the subject in need of an oral dosage form comprising an effective amount of a progestogen compound of formula (V) wherein R1 and R2 are hydrogens, an additional bond between carbons 1 and 2, or a CH2 bridge between carbons 1 and 2; and R3 and R4 are hydrogens or a CH2 bridge between carbons 15 and 16.

Overall, claim coverage centers on formula-defined progestogen structures with specified permissible double-bond and CH2-bridge options, and on producing a contraceptive state through oral administration of those formula progestogens, optionally including estrogen-containing regimens and explicit cyclic dosing patterns in dependent claims.

Stated Advantages

Produces a contraceptive state in a subject.

Documented Applications

Producing a contraceptive state in a subject by administering an oral dosage form comprising an effective amount of a progestogen compound of formula (II) or formula (V).

Oral dosage forms for producing a contraceptive state that additionally include an estrogen compound, including embodiments where ethinylestradiol is present.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.